Heidi Albert

Summary

Affiliation: Foundation for Innovative New Diagnostics
Country: Switzerland

Publications

  1. ncbi Feasibility of magnetic bead technology for concentration of mycobacteria in sputum prior to fluorescence microscopy
    Heidi Albert
    FIND, Foundation for Innovative New Diagnostics, Kampala, Uganda
    BMC Infect Dis 11:125. 2011
  2. ncbi Performance of three LED-based fluorescence microscopy systems for detection of tuberculosis in Uganda
    Heidi Albert
    Tuberculosis Research Laboratory, Foundation for Innovative New Diagnostics, Kampala, Uganda
    PLoS ONE 5:e15206. 2010
  3. ncbi Development of an antimicrobial formulation for control of specimen-related contamination in phage-based diagnostic testing for tuberculosis
    H Albert
    Biotec Laboratories Ltd, Somerset Hospital, Greenpoint, Cape Town, South Africa
    J Appl Microbiol 103:892-9. 2007
  4. ncbi Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda
    Heidi Albert
    Foundation for Innovative New Diagnostics, Kampala, Uganda
    BMC Infect Dis 10:41. 2010
  5. ncbi Improved contamination control for a rapid phage-based rifampicin resistance test for Mycobacterium tuberculosis
    Richard Mole
    Biotec Laboratories Ltd, Somerset Hospital, Greenpoint, Cape Town, South Africa
    J Med Microbiol 56:1334-9. 2007
  6. ncbi Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
    Catharina C Boehme
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    Lancet 377:1495-505. 2011
  7. ncbi Evaluation of a rapid screening test for rifampicin resistance in re-treatment tuberculosis patients in the Eastern Cape
    H Albert
    Biotec Laboratories Ltd, Somerset Hospital, Cape Town, South Africa
    S Afr Med J 97:858-63. 2007
  8. ncbi Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaqueTB-RIF, a manual phage-based test
    H Albert
    Biotec Laboratories Ltd, Johannesburg, South Africa
    Int J Tuberc Lung Dis 6:523-8. 2002
  9. ncbi Simple, phage-based (FASTPplaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum
    H Albert
    Biotec Laboratories Ltd, c o National Health Laboratory Service, Cape Town, Western Cape, South Africa
    Int J Tuberc Lung Dis 8:1114-9. 2004
  10. ncbi Performance of FASTPlaqueTB and a modified protocol in a high HIV prevalence community in South Africa
    Andre P Trollip
    Biotec Laboratories South Africa Ltd, Cape Town, South Africa
    Int J Tuberc Lung Dis 13:791-3. 2009

Collaborators

Detail Information

Publications12

  1. ncbi Feasibility of magnetic bead technology for concentration of mycobacteria in sputum prior to fluorescence microscopy
    Heidi Albert
    FIND, Foundation for Innovative New Diagnostics, Kampala, Uganda
    BMC Infect Dis 11:125. 2011
    ..Simpler concentration methods that could be applied in peripheral laboratories are urgently needed...
  2. ncbi Performance of three LED-based fluorescence microscopy systems for detection of tuberculosis in Uganda
    Heidi Albert
    Tuberculosis Research Laboratory, Foundation for Innovative New Diagnostics, Kampala, Uganda
    PLoS ONE 5:e15206. 2010
    ....
  3. ncbi Development of an antimicrobial formulation for control of specimen-related contamination in phage-based diagnostic testing for tuberculosis
    H Albert
    Biotec Laboratories Ltd, Somerset Hospital, Greenpoint, Cape Town, South Africa
    J Appl Microbiol 103:892-9. 2007
    ....
  4. ncbi Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda
    Heidi Albert
    Foundation for Innovative New Diagnostics, Kampala, Uganda
    BMC Infect Dis 10:41. 2010
    ..Line probe assays (LPAs) have been recently approved for use in low income settings and can be used to screen smear-positive sputum specimens for resistance to rifampicin and isoniazid in 1-2 days...
  5. ncbi Improved contamination control for a rapid phage-based rifampicin resistance test for Mycobacterium tuberculosis
    Richard Mole
    Biotec Laboratories Ltd, Somerset Hospital, Greenpoint, Cape Town, South Africa
    J Med Microbiol 56:1334-9. 2007
    ..Thus, the use of NOA improves the robustness of the test, facilitating its wider implementation...
  6. ncbi Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
    Catharina C Boehme
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    Lancet 377:1495-505. 2011
    ..We aimed to assess operational feasibility, accuracy, and effectiveness of implementation in such settings...
  7. ncbi Evaluation of a rapid screening test for rifampicin resistance in re-treatment tuberculosis patients in the Eastern Cape
    H Albert
    Biotec Laboratories Ltd, Somerset Hospital, Cape Town, South Africa
    S Afr Med J 97:858-63. 2007
    ..The ability of rifampicin resistance to predict MDR-TB was also determined...
  8. ncbi Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaqueTB-RIF, a manual phage-based test
    H Albert
    Biotec Laboratories Ltd, Johannesburg, South Africa
    Int J Tuberc Lung Dis 6:523-8. 2002
    ..A Mycobacteriology Reference Laboratory in Johannesburg, South Africa...
  9. ncbi Simple, phage-based (FASTPplaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum
    H Albert
    Biotec Laboratories Ltd, c o National Health Laboratory Service, Cape Town, Western Cape, South Africa
    Int J Tuberc Lung Dis 8:1114-9. 2004
    ..Cape Town, South Africa...
  10. ncbi Performance of FASTPlaqueTB and a modified protocol in a high HIV prevalence community in South Africa
    Andre P Trollip
    Biotec Laboratories South Africa Ltd, Cape Town, South Africa
    Int J Tuberc Lung Dis 13:791-3. 2009
    ..Before the FASTPlaqueTB can be considered as a viable replacement for smear microscopy and culture for the identification of tuberculosis, further work is required to resolve the performance issues identified in this study...
  11. ncbi Economic analysis of the diagnosis of smear-negative pulmonary tuberculosis in South Africa: incorporation of a new rapid test, FASTPlaqueTB, into the diagnostic algorithm
    H Albert
    Biotec Laboratories Ltd, c o National Health Laboratory Service, Cape Town, Western Cape, South Africa
    Int J Tuberc Lung Dis 8:240-7. 2004
    ....
  12. ncbi Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence
    O J Strauss
    DST NRF Centre of Excellence for Biomedical Tuberculosis Research MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa
    J Clin Microbiol 46:1514-6. 2008
    ..Transmission was linked to human immunodeficiency virus coinfection (P = 0.029), raising concern for the spread of drug resistance in vulnerable populations...